Machine Learning of Human Pluripotent Stem Cell-Derived Engineered Cardiac Tissue Contractility for Automated Drug Classification.

Journal: Stem cell reports
PMID:

Abstract

Accurately predicting cardioactive effects of new molecular entities for therapeutics remains a daunting challenge. Immense research effort has been focused toward creating new screening platforms that utilize human pluripotent stem cell (hPSC)-derived cardiomyocytes and three-dimensional engineered cardiac tissue constructs to better recapitulate human heart function and drug responses. As these new platforms become increasingly sophisticated and high throughput, the drug screens result in larger multidimensional datasets. Improved automated analysis methods must therefore be developed in parallel to fully comprehend the cellular response across a multidimensional parameter space. Here, we describe the use of machine learning to comprehensively analyze 17 functional parameters derived from force readouts of hPSC-derived ventricular cardiac tissue strips (hvCTS) electrically paced at a range of frequencies and exposed to a library of compounds. A generated metric is effective for then determining the cardioactivity of a given drug. Furthermore, we demonstrate a classification model that can automatically predict the mechanistic action of an unknown cardioactive drug.

Authors

  • Eugene K Lee
    Department of Biomedical Engineering, University of California, Irvine, Irvine, CA 92697, USA; Novoheart LTD, Shatin, Hong Kong.
  • David D Tran
    Novoheart LTD, Shatin, Hong Kong.
  • Wendy Keung
    Dr. Li Dak-Sum Research Centre, The University of Hong Kong - Karolinska Institutet Collaboration in Regenerative Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong; Ming-Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Stockholm 17177, Sweden.
  • Patrick Chan
    Dr. Li Dak-Sum Research Centre, The University of Hong Kong - Karolinska Institutet Collaboration in Regenerative Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong; Ming-Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Stockholm 17177, Sweden.
  • Gabriel Wong
    Novoheart LTD, Shatin, Hong Kong.
  • Camie W Chan
    Novoheart LTD, Shatin, Hong Kong.
  • Kevin D Costa
    Novoheart LTD, Shatin, Hong Kong; Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA.
  • Ronald A Li
    Novoheart LTD, Shatin, Hong Kong; Dr. Li Dak-Sum Research Centre, The University of Hong Kong - Karolinska Institutet Collaboration in Regenerative Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong; Ming-Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Stockholm 17177, Sweden.
  • Michelle Khine
    Department of Biomedical Engineering, University of California, Irvine, Irvine, CA 92697, USA; Novoheart LTD, Shatin, Hong Kong. Electronic address: mkhine@uci.edu.